On March 15, Pku Healthcare Corp.Ltd(000788) ( Pku Healthcare Corp.Ltd(000788) , Pku Healthcare Corp.Ltd(000788) ) announced that the company had never carried out the research and development of covid-19 specific drugs, nor had it discussed the cooperation with yanyeyi of Japan on covid-19 specific drugs.
As of March 15, Pku Healthcare Corp.Ltd(000788) ( Pku Healthcare Corp.Ltd(000788) ) five board limit rose to close at 12 yuan.
Previously, research institutions and media reported that Pku Healthcare Corp.Ltd(000788) (hereinafter referred to as ” Pku Healthcare Corp.Ltd(000788) “) was classified as covid-19 concept stock, and it was rumored that Pku Healthcare Corp.Ltd(000788) cooperated with yanyeyi pharmaceutical company of Japan (hereinafter referred to as “yanyeyi”) to develop covid-19 specific drugs.
On February 25, the covid-19 oral drug developed by yanyeyi officially submitted an application for clinical treatment approval to the Ministry of health, labor and welfare of Japan Ping An Insurance (Group) Company Of China Ltd(601318) Life Insurance Co., Ltd. (hereinafter referred to as “Ping An Life”) under Ping An Insurance (Group) Company Of China Ltd(601318) took a strategic stake in yanye in March 2020. According to some studies, Pku Healthcare Corp.Ltd(000788) as the only listing platform of Ping An Life Insurance, is expected to enjoy the exclusive sales right in China.
On March 13 before that, Pku Healthcare Corp.Ltd(000788) ( Pku Healthcare Corp.Ltd(000788) ) announced that the company has no plan to cooperate with foreign manufacturers.
According to the official website, Pku Healthcare Corp.Ltd(000788) is a core member enterprise of the medical and pharmaceutical industry of new Founder Group (Peking University Founder Group has been reorganized), and its products cover anti-tumor, psychoneurological, cardiovascular, immunosuppressive, anti microbial, antipyretic and analgesic, etc.
According to the ownership structure, Pku Healthcare Corp.Ltd(000788) is an enterprise under Peking University. Its major shareholder is southwest Synthetic Medicine Group Co., Ltd. and its second largest shareholder is Peking University Medical Industry Group Co., Ltd., which is regarded as an enterprise of “Peking University Department”.
Pku Healthcare Corp.Ltd(000788) 2021 third quarter report shows that the company’s operating revenue in the third quarter was 590 million yuan, an increase of 4.48% year-on-year (compared with the same period of the previous year); The net profit attributable to the shareholders of the listed company was 22.593 million yuan, a year-on-year increase of 41.05%.
